SPRUCE BIOSCIENCES, INC.
SPRBNasdaq
$43.54
↓ -1.7%Jul 17 close · end-of-day
Price
1Y↑ +476.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$59.7M
Enterprise Value
$12.1M
P/E
—
P/S
—
P/B
1.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$37.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-107.3%
ROIC
—
Debt / Equity
0.2
Net Cash
$47.6M
Return 1Y
+511.1%
Company profile
Spruce Biosciences, Inc. focuses on developing and commercializing novel therapies for rare endocrine disorders. The company is developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia.
- CEO
- Javier Szwarcberg
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- California
- Website
- www.sprucebiosciences.com
Earnings
SPRB Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$8.94↓ -62.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $10.1M | $4.9M | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$29.4M | -$42.1M | -$47.3M | -$52.0M | -$56.2M | -$36.5M |
| Net income | -$29.5M | -$42.3M | -$46.2M | -$47.9M | -$53.0M | -$39.0M |
| Diluted EPS | — | -$1.81 | -$1.96 | -$1.24 | -$96.40 | -$50.83 |
| Operating cash flow | -$27.5M | -$35.9M | -$41.7M | -$33.3M | -$56.0M | -$33.3M |
| Free cash flow | -$27.6M | -$36.0M | -$41.7M | -$33.3M | -$56.0M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | -515.3% | -1143.4% | — |
| Net margin | — | — | — | -475.0% | -1079.9% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6M | $602,000.00 | $697,000.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$10.0M | -$9.4M | -$24.1M | -$14.5M | -$2.7M | -$8.2M | -$11.1M | -$12.0M |
| Net income | -$9.2M | -$8.7M | -$23.6M | -$14.0M | -$2.1M | -$8.2M | -$14.6M | -$12.3M |
| Diluted EPS | -$16.73 | -$15.75 | -$63.64 | -$23.95 | -$3.50 | -$14.58 | -$8.80 | -$8.94 |
| Operating cash flow | -$11.1M | -$9.2M | -$20.7M | -$12.7M | -$8.8M | -$5.3M | -$6.5M | -$8.7M |
| Free cash flow | — | — | — | -$12.7M | — | — | — | -$8.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -623.4% | -1562.8% | -3453.9% | — | — | — | — | — |
| Net margin | -570.2% | -1440.4% | -3380.1% | — | — | — | — | — |
Company news
Jul 13, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.